Vetter Pharma
- Max Horn
- Thomas Otto
- Peter Sölkner
The Vetter Pharma Manufacturing GmbH & Co. KG is an existing since 1953 German pharmaceutical suppliers based in the Baden -Württemberg Ravensburg. With an annual production of about 400 million units cousin is a world leader in pre-filled injection systems.
History
The company was founded in 1953 by the pharmacist Helmut Vetter ( 1920-1999 ) as a pharmacist cousin & Co. Arzneimittel GmbH Ravensburg. Cousin had been since 1945 a chemical- pharmaceutical laboratory since 1950 and operated as a tenant also the traditional Marienapotheke in Ravensburg. First, the operation mainly focused cachets, especially the self-developed stomach means " Ullus capsules ". The rapidly expanding company moved a year later in a four-story building in the center of Ravensburg. Opened in 1958 Vetter own pharmacy (pharmacy cousin at Marienplatz ), including perfumery and health food store. During this time, cousin began, primarily to deal with the air-and watertight sealing of the drugs themselves produced. In 1965 the company began with the contract manufacturing of solid and liquid medicines, including their packaging. Since 1975 aseptically filled syringes are produced amplified. In the United States cousins founded in 1983 its first foreign subsidiary, Vetter Pharma -Turm Inc. in Yardley (Pennsylvania), which took over the sales in the U.S. and Canada. 1984 the company was renamed Vetter Pharma Manufacturing GmbH & Co. KG.
In Ravensburg in 1988 received the work authorization of the U.S. FDA, what the U.S. market opened. Two years later, the company launched a new dual-chamber syringe system on the market that contains freeze-dried in a chamber and therefore long -lasting drug and in the second chamber, a suitable solvent; upon application, the components are mixed. In the next few years, the production has been largely automated. In Langenargen a second German production facility was established in 1996, which also received FDA approval in 1998. The growing operation was expanded in 2004 with the construction of a second plant in Ravensburg -South ( commercial area Mariatal ). The production facility was completed in late 2006 and early 2007 received a production permit from the Regional Council of Tübingen, one year later the FDA approval. The end of 2007 began in Ravensburg Vetter South with the construction of a new plant for the final, which was fully commissioned in May. At Ravensburg South also in 2009 a laboratory for production accompanied analysis was built. In 2009 the company established the sales subsidiary Vetter Pharma International GmbH, the U.S. subsidiary was renamed Vetter Pharma International USA Inc.. In December 2009, the company opened a development office in Chicago. There, small amounts of active ingredient are filled during the development of new drugs for clinical trials. In May 2012, Cousin placed ready to be new center for visual inspection and logistics, which is equipped with technologies for the production of renewable energy and improve energy efficiency.
Today, cousin concentrated with around 2,800 employees at several locations in Germany and an overseas branch in the USA ( Chicago) to the aseptic filling of syringes (such as cartridges ) with drugs and their packaging.
In addition to the management team consisting of three directors, an independent Advisory Board assists the company in an advisory capacity. Since 2008, Udo J. Vetter is chairman of the advisory board.
Importance
The U.S. Department of Homeland Security led Vetter 2008 on the strategy list of the Critical Foreign Dependencies Initiative. This captures foreign infrastructure that would cover if attacked or destroyed, jeopardizing the United States ( "foreign infrastructure Which if attacked or destroyed would critically impact the U.S. ").